Prognostic factors in patients with stage II colon cancer: Role of E-selectin gene polymorphisms

2019 ◽  
Vol 51 (8) ◽  
pp. 1198-1201
Author(s):  
Anthony Turpin ◽  
Julien Labreuche ◽  
Jean-François Fléjou ◽  
Thierry Andre ◽  
Aimery de Gramont ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Gene Polymorphisms ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

The effect of chemotherapy on overall survival of stage II colon cancer.

2011 ◽  
Vol 29 (4_suppl) ◽  
pp. 625-625
Author(s):  
M. Omaira ◽  
M. Mozayen ◽  
K. Katato
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Survival Rate ◽  
Survival Rates ◽  
Stage Ii ◽  
Disease Stage ◽  
Overall Survival Rate ◽  
Significant Difference ◽  
Stage Ii Colon Cancer

625 Background: Surgical resection of local colon cancer is the only curative treatment, at the same time adjuvant chemotherapy is clearly shown to be beneficial as the standard of care for node positive disease (stage III) colon cancer. However the role of chemotherapy for stage II colon cancer treatment is still conflicting. We aim to compare the overall survival rate of stage II colon cancer patient's with and without chemotherapy. Methods: A retrospective observational study was conducted from 1990-2006. Patients with stage II colon cancer were included. Patient's characteristics including age, gender, common site of involvement, histology patterns, overall survival rate and treatment with chemotherapy were recorded. Results: A total of 138 consecutive patients were identified from 1990-2006. The median age was 68 (21-91) year, males (44%), African Americans (47.6%). The most common sites of the primary tumor were sigmoid and cecum (22.4%) each. Adenocarcinoma being the most common pathology. Majority of the patients (86.2%) were found to have T 3 tumors. Of the patients that received chemotherapy (29/44) 66% had an overall survival rate of three years or more, whereas (53/94) 57% of the patients who did not receive chemotherapy had a survival rate of three years or more. The difference of survival rates between the two groups of patients was not statistically significant. Conclusions: The role of chemotherapy in stage II colon ancer is still controversial. There was no significant difference in overall survival between the two groups who did and did not receive chemotherapy; thus more studies are warranted to explore the factors that predict the survival of stage II colon cancer. No significant financial relationships to disclose.

Prognostic factors in stage II colon cancer after radical resection.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14604-e14604
Author(s):  
Nieves Martinez Lago ◽  
Maria Vieito ◽  
Rafael Varela Ponte ◽  
Carmela Rodriguez ◽  
Sonia Candamio ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Radical Resection ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

Association between ColDx assay result and recurrence-free interval in stage II colon cancer patients on CALGB (Alliance) 9581.

2014 ◽  
Vol 32 (3_suppl) ◽  
pp. 455-455 ◽  
Author(s):  
Donna Niedzwiecki ◽  
Wendy Frankel ◽  
Alan Paul Venook ◽  
Xing Ye ◽  
Paula N. Friedman ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Gene Expression Signature ◽  
Stage Ii ◽  
Phase Iii ◽  
Eligibility Criteria ◽  
Accurate Identification ◽  
Free Interval ◽  
Assay Result ◽  
Stage Ii Colon Cancer

455 Background: Only 15-25% of pts with stage II colon cancer (CC) experience recurrence and conventional staging methods neither allow accurate identification of low (L) and high-risk (H) subgroups nor predict benefit of adjuvant chemotherapy. The ColDx assay (Almac Diagnostics) is a 634-probeset gene expression signature shown to be independently prognostic for recurrence-free interval (RFI). The objective of this study was to assess the ability of ColDx to classify stage II CC pts at L- and H-risk of relapse. Methods: This validation study was conducted using formalin fixed paraffin embedded biospecimens and clinical data from CALGB 9581, a phase III trial of edrecolomab v. observation in pts with normal risk, stage II CC. 1,454 CALGB 9,581 pts met eligibility criteria. A case-cohort sampling design was used to randomly select (RS) 514 pts from 901 eligible pts with available tissue; supplemented by 49 non-RS recurrent pts (total 563). Risk status for each pt was based on a positive or negative ColDx score using a pre-specified cutpoint, 0.4377. The Self Prentice method was used to test the association between ColDx categories and RFI (distant recurrence or death due to primary disease). Results: Initial results in 563 pts were erroneous due to a quality failure in a batch of reagent. 524 samples were re-labeled, re-ordered, and re-assayed using reagents that passed quality control (36 samples had insufficient material; 95 failed ColDx QC). Final analysis comprised 393 pts, 360 RS (58 events; 16%); 33 non-RS events. 216 pts (55%) were predicted H (62 events); 177 (45%) pts were predicted L (29 events). H pts exhibited significantly worse RFI (univariable hazard ratio (HR), 2.0; 95% CI, 1.3-3.3; p < 0.01). ColDx remained significant after adjustment for prognostic factors; HR, 2.1 (95% CI, 1.3-3.4; p < 0.01). Conclusions: The ColDx assay result is associated with RFI in the CALGB 9,581 sub-sample and is independent from other prognostic factors, including MSI. Further investigation is needed to establish the role of this classifier in guiding treatment decisions in this patient population.

scholarly journals How does adjuvant chemotherapy for stage II colon cancer impact survival in regard of prognostic factors? A report of 147 Tunisian cases

2019 ◽  
Vol 30 ◽  
pp. iv108-iv109
Author(s):  
S. Sghaier ◽  
H. Rachdi ◽  
N. Mejri ◽  
B. Graja ◽  
S. Labidi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

scholarly journals Evaluation of relapse-free survival in T3N0 colon cancer: The role of chemotherapy—A multicentric retrospective analysis.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14082-e14082
Author(s):  
Roberta Grande ◽  
Maurizio Cosimelli ◽  
Donatello Gemma ◽  
Fabrizio Ciancola ◽  
Domenico C. Corsi ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Disease Free Survival ◽  
Stage Ii ◽  
Operating Characteristics ◽  
Relapse Free Survival ◽  
Node Number ◽  
Free Survival ◽  
Group 5

e14082 Background: Use of adjuvant chemotherapy (AC) in Stage II Colon Cancer (CC) is still under debate. Choice should be based on patients (pts) and disease characteristics. According to worldwide guidelines AC should be considered in high-risk (H) T3N0 pts. No data are available for better option in low-risk (L) pts. Aim of the study is to evaluate relapse-free survival (RFS) and disease-free survival (DFS) retrospectively in T3N0 CC pts related to treatment. Methods: RFS and DFS are evaluated with Kaplan Meier method. In order to find the optimal cut off for node number the receiver operating characteristics curve analysis and Maximally Selected Rank Statistics were performed. Multivariate Cox proportional hazard model was developed using stepwise regression, enter limit and remove limit were p = 0.10 and p = 0.15 respectively. Results: 1,000 pts with T3N0 CC were recruited. To date, data of 926 pts are available. Median age was 69 (29-93), M/F 513/413, Grading 1/2/3 46/668/158; 360 L (39%), 411 H (44%), 155 unknown (17%); 137 (15%) pts showed symptoms (S) at diagnosis: 51 pts had perforation (P) or bowel obstruction (BO). Median sampled lymph nodes (LN) were 15 (1-76); 383 (41%) pts were treated with AC. Median follow up (fu) was 5 years (yr) (range 3-24). Survival analysis was performed only for pts with a minimum fu of 3 yr and younger than 80 (80%). 5 yr RFS was 78% and 5 yr DFS was 76% At multivariate analysis S and AC were prognostic factors for RFS. AC is prognostic factor for all endpoints (data are shown in table). In L group 5 yr RFS was 88% in treated pts and 75% in non-treated pts (p 0.03); in H group was respectively 82% and 72% (p 0.006). Conclusions: Preliminary data confirmed the role of known prognostic factors and suggest the relevance of AC also in L stage II T3N0 CC pts. However, the highest risk in L subgroup should be identified to be submitted to AC. Data collection is ongoing, update results will be presented. [Table: see text]

Prognostic factors of overall survival for patients with stage II colon cancer treated at Sparrow Hospital from 1996–2006

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 15089-15089
Author(s):  
G. Srkalovic ◽  
M. Maier ◽  
U. Chamarthy ◽  
L. DiCarlo ◽  
G. Pearce ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Stage Ii ◽  
Stage Ii Colon Cancer

Microsatellite instability as a prognostic factor in stadium II colon cancer patients. A meta-analysis of published literature.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15075-e15075
Author(s):  
Jan Novotny ◽  
Ioannis Gkekas ◽  
Ladislav Pecen ◽  
Karin Strigard ◽  
Richard Palmquist ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Microsatellite Instability ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Stage Ii ◽  
Survival Outcomes ◽  
Prognostic Role ◽  
Hazard Ratios ◽  
Stage Ii Colon Cancer

e15075 Background: The prognostic role of microsatellite instability (MSI) in stage II colon cancer patients remains controversial despite it has been investigated in a number of studies. Hazard ratios differ considerably among these studies. We performed a meta-analysis to define the significance of MSI in this group of patients. Methods: Studies indexed in PubMed presenting separate data on MSI status and survival outcomes for stage II colon cancer patients have been analyzed using fixed-effect meta-analysis of hazard ratio according to the method of Peto. Results: Analysis was performed on 19 studies including 5998 patients. 47.2% patients received postoperative chemotherapy, 52.8% were males and 47.2% females. Eight studies included also rectal cancer patients. MSI was detected in 20.8 % of the patients. Hazard ration (HR) for overall survival (OS): MSI vs MSS for the entire population: 0.73 (95% confidence interval (CI): 0.33-1.65); HR for disease free survival (DFS): 0.60 (95% CI: 0.27-1.32). No statistical significant difference was found when comparing studies analyzing MSI with genotyping (MG) and immunohistochemistry (IHC) (MG vs IHC: HR OS 0.45, 95% CI 0.10-2.05 vs. 0.95, 95% CI 0.57–1.58; HR DFS 0.51, 95% CI: 0.14-1.85 vs. 0.67, 95% CI 0.26-1.70). However, numerically MSI determination with genotyping shows remarkably lower hazard ratios (further from HR equal to one) for both OS and DFS. Separate analysis of studies investigating colon cancer patients only showed HR OS 0.72 (95% CI: 0.31-1.71); HR DFS 0.60 (95% CI: 0.27-1.31). Conclusions: This is the first meta-analysis that evaluates the prognostic role of MSI in the well defined population of colon cancer patients with stage II disease. No significant relation was found between MSI status and various survival outcomes. Routine determination of MSI status to guide postoperative management of stage II colon cancer patients cannot be recommended based on the presently included studies. This study was supported from the unrestricted grant of Cancerforskningsfonden i Norrland/Lions Cancerforskningsfond LP 14-2065 and Akademisk Miljö NLL-576531.

scholarly journals P-124 Tumor budding and CDX2 as additional prognostic factors in stage II colon cancer

2020 ◽  
Vol 31 ◽  
pp. S130
Author(s):  
M. Roberto ◽  
D. Ierinò ◽  
M. Panebianco ◽  
A. Romiti ◽  
A. Di Cerbo ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Stage Ii ◽  
Tumor Budding ◽  
Stage Ii Colon Cancer

scholarly journals Survival and prognostic factors for stage II colon cancer

2019 ◽  
Vol 30 ◽  
pp. iv105
Author(s):  
S. Berrad ◽  
K. Oualla ◽  
l. nouiyakh ◽  
H. Erraichi ◽  
Z. benbrahim ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Stage Ii ◽  
Stage Ii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document